Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tumor response in comparative trials].

A Laplanche1

  • 1Département de biostatistique et d'épidémiologie, institut Gustave-Roussy, Villejuif, France.

Bulletin Du Cancer
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential time to positivity of central and peripheral blood cultures is inaccurate for the diagnosis of Staphylococcus aureus long-term catheter-related sepsis.

The Journal of hospital infection·2018
Same author

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

European journal of cancer (Oxford, England : 1990)·2017
Same author

[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2015
Same author

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma?

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

[Prospective economic evaluation of image-guided radiation therapy for prostate cancer in the framework of the national programme for innovative and costly therapies assessment].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2012
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles

Tumor response is a common cancer trial endpoint for quick results in phase II studies. However, it is not suitable for phase III comparative trials due to several limitations discussed herein.

Area of Science:

  • Oncology
  • Clinical Trial Design

Context:

  • Cancer clinical trials frequently use tumor response as a surrogate endpoint.
  • This metric allows for rapid assessment of treatment effects.

Purpose:

  • To evaluate the suitability of tumor response as a primary endpoint in cancer trials.
  • To highlight the limitations of using tumor response in phase III comparative studies.

Summary:

  • Tumor response is a valuable screening tool in phase II cancer trials.
  • Its use in phase III comparative trials is problematic due to several factors.
  • Survival improvement remains the definitive goal in cancer research.

Impact:

  • Provides critical insights into endpoint selection for cancer clinical trials.

Related Experiment Videos

  • Informs researchers on the appropriate use of tumor response metrics.
  • Contributes to the design of more robust and meaningful phase III cancer studies.